Menarini Group and Insilico Medicine enter global exclusive license agreement for novel KAT6 inhibitor for potential breast cancer treatment and other oncology indications
● KAT6 is an emerging target in hormone sensitive breast tumors and other cancers. Overexpression of KAT6A/B correlates with poor clinical outcomes in patients with ER+/HER2- breast cancer – the most common subtype.
● The molecule has demonstrated strong preclinical activity. Insilico Medicine presented data on the novel molecule at the San Antonio Breast Cancer Symposium in early December.
● This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.
FLORENCE, Italy and NEW YORK: The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, ...












